77 related articles for article (PubMed ID: 10101145)
1. Effect of its demethylated metabolite on the pharmacokinetics of unchanged TAK-603, a new antirheumatic agent, in rats.
Tagawa Y; Miwa K; Tsukuda R; Yoshimura Y; Tanayama S; Tanigawara Y
Drug Metab Dispos; 1999 Apr; 27(4):495-501. PubMed ID: 10101145
[TBL] [Abstract][Full Text] [Related]
2. Disposition of the new antirheumatic agent ethyl 4-(3,4-dimethoxyphenyl)- 6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) in rats and dogs.
Tagawa Y; Kiyota Y; Yoshimura Y; Motohashi M; Tanayama S
Arzneimittelforschung; 1998 Jul; 48(7):750-7. PubMed ID: 9706376
[TBL] [Abstract][Full Text] [Related]
3. Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats.
Tagawa Y; Miwa K; Yamashita K; Tsukuda R; Yoshimura Y; Tanayama S; Tanigawara Y
Biopharm Drug Dispos; 1999 Jan; 20(1):11-8. PubMed ID: 10086833
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of radiolabelled quinlukast in rats.
Syrovatko M; Laznickova A; Laznicek M
J Pharm Biomed Anal; 2005 Jun; 38(2):313-9. PubMed ID: 15925224
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective disposition and chiral inversion of KE-298, a new antirheumatic drug, in rats.
Yoshida H; Kohno Y; Endo H; Ohmi N; Fukushima K; Suwa T; Hayashi M
Chirality; 1997; 9(1):22-8. PubMed ID: 9094199
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction between TAK-044, a new endothelin antagonist, and ciclosporin in rats.
Maeshiba Y; Yamashita K; Tsukuda R; Yoshimura Y
Arzneimittelforschung; 2002; 52(9):664-8. PubMed ID: 12404880
[TBL] [Abstract][Full Text] [Related]
9. Acute dose-dependent disposition studies of nicotinic acid in rats.
Iwaki M; Ogiso T; Hayashi H; Tanino T; Benet LZ
Drug Metab Dispos; 1996 Jul; 24(7):773-9. PubMed ID: 8818575
[TBL] [Abstract][Full Text] [Related]
10. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
[TBL] [Abstract][Full Text] [Related]
12. Absorption and enterohepatic circulation of baicalin in rats.
Xing J; Chen X; Zhong D
Life Sci; 2005 Nov; 78(2):140-6. PubMed ID: 16107266
[TBL] [Abstract][Full Text] [Related]
13. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
15. Effect of enterohepatic circulation on the pharmacokinetics of diflunisal in rats.
Lin JH; Yeh KC; Duggan DE
Drug Metab Dispos; 1985; 13(3):321-6. PubMed ID: 2861991
[TBL] [Abstract][Full Text] [Related]
16. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
[TBL] [Abstract][Full Text] [Related]
17. Studies on disease-modifying antirheumatic drugs. II. Synthesis and activity of the metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quino line-3-carboxylate (TAK-603).
Baba A; Makino H; Ohta Y; Sohda T
Chem Pharm Bull (Tokyo); 1998 Jul; 46(7):1130-4. PubMed ID: 9692219
[TBL] [Abstract][Full Text] [Related]
18. Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations.
Harrison A; Betts A; Fenner K; Beaumont K; Edgington A; Roffey S; Davis J; Comby P; Morgan P
Drug Metab Dispos; 2004 Feb; 32(2):197-204. PubMed ID: 14744941
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
20. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
